Astrotech Corp income statement
In fiscal 2026, Astrotech Corp reported revenue of $913,000, down 8.7% on the year before, operating income of −$14.1m (a -1548.5% margin) and net income of −$14.4m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2011Jun 2011 | 2012Jun 2012 | 2013Jun 2013 | 2014Jun 2014 | 2015Jun 2015 | 2016Jun 2016 | 2017Jun 2017 | 2018Jun 2018 | 2019Jun 2019 | 2020Jun 2020 | 2021Jun 2021 | 2022Jun 2022 | 2023Jun 2023 | 2024Jun 2024 | 2025Jun 2025 | 2026Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20 | 26 | 24 | 0 | 1 | 3 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 1 |
| Cost of revenue | 14 | 19 | 16 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 |
| Gross profit | 6 | 7 | 8 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Research and development | 4 | 3 | 2 | 3 | 3 | 6 | 6 | 6 | 4 | 3 | 3 | 3 | 6 | 7 | 8 | 6 |
| Selling, general and administrative | 8 | 7 | 7 | 8 | 13 | 8 | 8 | 6 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 8 |
| Operating income | −6 | −2 | −1 | −10 | −16 | −14 | −12 | −13 | −8 | −8 | −8 | −9 | −11 | −13 | −15 | −14 |
| Interest expense | — | — | — | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — |
| Income before tax | −6 | −3 | −1 | −10 | −16 | −13 | −12 | −13 | −8 | −8 | −8 | −8 | −10 | −12 | −14 | −14 |
| Income tax | −0 | 0 | 0 | −4 | −6 | −0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −5 | −3 | −0 | −5 | 11 | −13 | −12 | −13 | −8 | −8 | −8 | −8 | −10 | −12 | −14 | −14 |
| Diluted EPS | −$42.00 | −$22.50 | $1.50 | $37.50 | $78.00 | −$19.20 | −$85.20 | −$97.80 | −$45.90 | −$39.30 | −$10.50 | — | — | — | — | — |
| Diluted shares (average) | — | — | — | — | — | — | — | — | — | — | — | 2m | 2m | 2m | 2m | 2m |
| EBITDA | −3 | −0 | 2 | −10 | −16 | −13 | −11 | −13 | −8 | −8 | −8 | −8 | −11 | −13 | −14 | −13 |
| Quarter | 2025 Q1Sept 2024 | 2025 Q2Dec 2024 | 2025 Q3Mar 2025 | 2025 Q4Jun 2025 | 2026 Q1Sept 2025 | 2026 Q2Dec 2025 | 2026 Q3Mar 2026 | 2026 Q4Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 34 | 261 | 534 | 220 | 297 | 148 | 343 | 913 |
| Cost of revenue | 25 | 106 | 297 | 146 | 109 | 140 | 276 | 171 |
| Gross profit | 9 | 155 | 237 | 74 | 188 | 8 | 67 | −45 |
| Research and development | 1,949 | 2,437 | 1,989 | 1,767 | 1,944 | 1,832 | 1,435 | 1,273 |
| Selling, general and administrative | 1,688 | 2,039 | 2,115 | 1,225 | 1,780 | 2,077 | 2,085 | 1,930 |
| Operating income | −3,628 | −4,321 | −3,867 | −2,918 | −3,536 | −3,901 | −3,453 | −3,248 |
| Income before tax | 3,300 | −4,009 | −3,633 | −2,928 | 3,500 | −3,927 | −3,768 | −3,262 |
| Income tax | 0 | 0 | — | — | — | 0 | — | — |
| Net income | −3,278 | −4,009 | −3,633 | −2,930 | −3,465 | −3,927 | −3,768 | −3,266 |
| EBITDA | −3,396 | −4,082 | −3,620 | −2,674 | −3,300 | −3,679 | −3,226 | −3,036 |
Compare with peers
- Quantum-si Inc income statement
- Bionexus Gene Lab Corp income statement
- YD Bio Ltd income statement
- Ispecimen Inc. income statement
- Seer, Inc. income statement
Head to head: ASTC vs QSIASTC vs BGLCASTC vs YDES
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies